Estrogen Discontinuation and Blood Pressure: Evidence‑Based Guidelines

Effects of Estrogen on Blood Pressure

The Women’s Health Initiative reported that combined estrogen‑progestin therapy produced a mean increase of ≈1 mmHg in systolic blood pressure over 5.6 years, a change considered clinically insignificant【1】.
In transgender women receiving estrogen (often together with anti‑androgens), research showed no significant rise in hypertension incidence and, in some analyses, a modest reduction in systolic blood pressure【2】【3】.

Standard antihypertensive therapy should be used rather than restarting estrogen when elevated blood pressure appears after stopping estrogen therapy【1】.
The target blood pressure for most adults is 120–129 mmHg systolic / 70–79 mmHg diastolic when pharmacologic treatment is indicated【1】.
For confirmed blood pressure ≥140/90 mmHg, initiate a two‑drug regimen (an ACE inhibitor or ARB plus a calcium‑channel blocker) as first‑line therapy【1】.
Blood pressure should be monitored closely for 3–6 months after estrogen discontinuation to detect any clinically relevant changes that may require intervention【1】.

The American Heart Association classifies the initiation of estrogen‑progestin therapy for cardiovascular disease prevention as Class III (harmful) with Level A evidence, noting increased risks of coronary heart disease (+29 %), stroke (+41 %), and venous thromboembolism (≈2‑fold)【1】.

Stopping estrogen may have significant psychological effects, including reduced quality of life and occupational satisfaction, which should be weighed against cardiovascular considerations【4】.
>40 % of post‑menopausal women develop hypertension independent of hormone therapy, indicating that any rise in blood pressure after estrogen cessation may reflect normal age‑related changes rather than a direct withdrawal effect【1】.